Pfizer-BioNTech Three-Dose COVID-19 Vaccine Regimen 80% Effective In Children Under Five Years, Preliminary Data Show

The Washington Post (5/23) reports Pfizer and BioNTech “said Monday that an early analysis showed their three-dose coronavirus vaccine regimen triggered a strong immune response in younger children, proving 80 percent effective at preventing symptomatic infections in children 6 months to 4 years old.” The companies “said they plan to finish filing data, which has not been peer reviewed, with the FDA this week,” but they “warned that the efficacy number was fluid because results are still arriving.”

Reuters (5/23) reports the companies “said that three shots of a 3 microgram formulation of their vaccine generated a similar immune response in that age group as in 16 to 25-year-olds who had received two doses of the 30 microgram formulation of the vaccine in an earlier clinical trial.”

The New York Times (5/23) and the AP (5/23) also report.

FURTHER READING

Pfizer: 3-dose COVID-19 vaccine 80% effective in children under 5